And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is exceedingly modest, however. We plan to hang with one of our short people, catch up on some reading, and check in on the Pharmalot ancestors. And what about you? Spring is now — finally — here, so you can start cleaning out your castle, manicuring the grounds, and, hopefully, enjoy some time in the great outdoors. Speaking of which, perhaps you want to check on the extent to which those of you situated near certain bodies of water may be affected by climate change, assuming you believe in that sort of thing. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon. …

President Trump’s ability to get his revised North American Free Trade Agreement through Congress may hinge on a little-noticed provision governing intellectual property protections for new medicines, the New York Times writes. Congressional Democrats have seized on measures in the United States-Mexico-Canada Agreement that establishes protections for drug makers, saying they are a boon to the pharmaceutical industry and could undermine efforts to make American health care more affordable.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy